ESR1 and breast cancer: The ensuing PALOMA-3 trial has also indicated that palbociclib in addition to the ER inhibitor fulvestrant improves overall survival (OS) in ER-positive and HER2-negative BC patients showing disease progression after endocrine therapy [27].